- Home
- SNOA vs SCNI Comparison
SNOA vs SCNI Comparison
Compare SNOA & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNOA
- SCNI
- Stock Information
- Founded
- SNOA 1999
- SCNI 2003
- Country
- SNOA United States
- SCNI Israel
- Employees
- SNOA N/A
- SCNI N/A
- Industry
- SNOA Biotechnology: Pharmaceutical Preparations
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNOA Health Care
- SCNI Health Care
- Exchange
- SNOA Nasdaq
- SCNI Nasdaq
- Market Cap
- SNOA 3.7M
- SCNI 3.1M
- IPO Year
- SNOA 2007
- SCNI N/A
- Fundamental
- Price
- SNOA $2.65
- SCNI $3.51
- Analyst Decision
- SNOA
- SCNI
- Analyst Count
- SNOA 0
- SCNI 0
- Target Price
- SNOA N/A
- SCNI N/A
- AVG Volume (30 Days)
- SNOA 44.7K
- SCNI 8.1K
- Earning Date
- SNOA 02-06-2025
- SCNI 11-22-2024
- Dividend Yield
- SNOA N/A
- SCNI N/A
- EPS Growth
- SNOA N/A
- SCNI N/A
- EPS
- SNOA N/A
- SCNI 8.20
- Revenue
- SNOA $13,547,000.00
- SCNI $452,000.00
- Revenue This Year
- SNOA $23.89
- SCNI N/A
- Revenue Next Year
- SNOA $25.45
- SCNI N/A
- P/E Ratio
- SNOA N/A
- SCNI $0.43
- Revenue Growth
- SNOA 11.81
- SCNI N/A
- 52 Week Low
- SNOA $2.44
- SCNI $2.23
- 52 Week High
- SNOA $9.40
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- SNOA 47.13
- SCNI 52.75
- Support Level
- SNOA $2.52
- SCNI $3.41
- Resistance Level
- SNOA $2.80
- SCNI $3.80
- Average True Range (ATR)
- SNOA 0.13
- SCNI 0.18
- MACD
- SNOA 0.00
- SCNI -0.00
- Stochastic Oscillator
- SNOA 39.39
- SCNI 36.42
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.